论文部分内容阅读
2004年7月7日——这天,以重庆康尔威药业有限公司为主要发起人的“伟哥联盟”全体成员:中国12家制药企业纷纷接到了国家知识产权局的电话通知,他们针对美国辉瑞公司治疗阳瘘的药品“万艾可”(英文名Viagra,俗称“伟哥”)的主要成分枸橼酸西地那非的应用专利无效申请中得到支持,国家知识产权局做出复审裁定:美国辉瑞公司“万艾可”专利无效。这一决定对于这12家甚至更多的国内制药企业来说,是莫大的喜讯,意味着其可以光明正大地生产“伟哥”类药品而不需要交一分钱的专利使用费了——要知道,国内制药企业等待这一天已经快三年的时间了,而对于广大阳瘘患者来说,也是莫大的福音——其很快就能以20多元的价格买到现市价为148元一粒的“万艾可”的替代品。当然,对于美国辉瑞公司来说,曾经以为可以享受到2014年的市场垄断权也正在消消溜走……
July 7, 2004 - On that day, all members of the “Viagra Alliance”, with Chongqing Kang Erwei Pharmaceutical Co., Ltd. as the main sponsor: 12 Chinese pharmaceutical companies have received phone calls from the State Intellectual Property Office in response to their requests The United States Pfizer treatment of fistula drugs, “Viagra” (English name Viagra, commonly known as “Viagra”) application of sildenafil citrate patent application is invalid, the State Intellectual Property Office to review the decision: the United States Pfizer's “Viagra” patent is invalid. The decision is a boon to the 12 or even more domestic pharmaceutical companies, which means they can produce “Viagra” drugs at fair prices without having to pay a penny for the royalties - to know , The domestic pharmaceutical companies have been waiting for this day has almost three years time, and for the majority of patients with positive fistula, is also a great blessing - its price will soon be able to 20 yuan to buy the current market price of 148 yuan a “Viagra” alternative. Of course, for the US Pfizer, it was thought that the monopoly of the market in 2014 was being eliminated.